Biotech / Medical : MGNX -- MacroGenics
MGNX 22.99+1.4%Jun 22 8:00 PM EDTNews

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (46)8/3/2017 1:02:21 PM
From: Miljenko Zuanic  Read Replies (1) of 109
<I think it is worth waiting for the next year of data to come in before rationalizing the pipeline. If they haven't found something to prune by then, I'll get worried.>

The point is to do this ahead of P1 results (early), from competitive landscape and in-house toxicology/efficacy model.

Yes, at this point I think that their PD1 (0012) is outdated (from efficacy model standpoint), and they are still talking about combining IT with in-house candidates? HYPE!!!! OR true waste of the company source????

So, If they think that their bi-specific IO is OK, and from preclinical data one would think so,...why not push in this direction????

IF they can bring 50-50 partner (US, and WW right)...well.......
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.